Future investigation on NF‐κB as an anti‐cancer target should focus on inhibiting its tumor‐promoting effects caused by pathological NF‐κB activation while avoiding affecting their normal physiological functions; meanwhile, the combination of multiple drugs targeting different key regulators of the NF‐κB pathway, even multiple pathways, is also attractive. The gene discussed is NFKB1; the disease is cancer.